VVY Vivoryon Therapeutics N.V.
Price Chart
Executive Summary
Vivoryon reported Q1 2026 results with no revenue, a net loss of EUR 1.8M (improved from EUR 2.5M a year ago), and cash of EUR 4.0M, sufficient into Q4 2026. The company highlighted compelling kidney function data from Phase 2 studies of varoglutamstat and ongoing partnership discussions, but all future development is contingent on additional funding.
Actionable Insight
Monitor partnership announcements or financing events as the primary catalyst. The cash runway into Q4 2026 provides a timeline for deal-making; failure to secure funding before then would risk going concern. The Phase 2b DKD study initiation is the key value inflection point.
Key Facts
- No revenue generated in Q1 2026.
- Net loss of EUR 1.8 million, improved from EUR 2.5 million in Q1 2025.
- Cash and cash equivalents of EUR 4.0 million as of March 31, 2026.
- Cash runway guidance: sufficient into Q4 2026, subject to no unforeseen circumstances.
- Phase 2b DKD study initiation and all future studies subject to additional funding/partnership.
- Active due diligence processes with multiple potential partners.
- Compelling kidney function data from VIVIAD and VIVA-MIND Phase 2 studies presented at WCN 2026.
Financial Impact
Net loss improved by EUR 0.7 million year-over-year; cash burn rate reduced. No revenue.
Risk Factors
- Going concern risk if additional funding not secured before cash depletion in Q4 2026.
- Dependence on partnership or financing to advance Phase 2b study.
- No revenue and continued operating losses.
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310182 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
4d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Jun 8, 2026
7d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 23, 2026
7w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 15, 2026
8w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 9, 2026
9w ago
|
Press Release
| — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access